Peripheral blood WT1 expression predicts relapse in AML patients undergoing allogeneic stem cell transplantation

BioMed Research International

Volumn 2014, Issue , 2014, Pages

  Malagola, Michele ^a   Skert, Cristina ^a   Ruggeri, Giuseppina ^a   Turra, Alessandro ^a   Ribolla, Rossella ^a   Cancelli, Valeria ^a   Cattina, Federica ^a   Alghisi, Elisa ^a   Bernardi, Simona ^a   Perucca, Simone ^a   Di Palma, Andrea ^a   Borlenghi, Erika ^a   Pagani, Chiara ^a   Rossi, Giuseppe ^a   Caimi, Luigi ^a   Russo, Domenico ^a  

^a SPEDALI CIVILI   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

WT1 PROTEIN; WT1 PROTEIN, HUMAN;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; BONE MARROW; CLINICAL ARTICLE; HUMAN; LEUKEMIA RELAPSE; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; ALLOTRANSPLANTATION; BLOOD; LEUKEMIA, MYELOID, ACUTE; MIDDLE AGED; PATHOLOGY; PROGNOSIS; STEM CELL TRANSPLANTATION; TREATMENT OUTCOME; TUMOR RECURRENCE;

ADULT; HUMANS; LEUKEMIA, MYELOID, ACUTE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; STEM CELL TRANSPLANTATION; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME; WT1 PROTEINS;

EID: 84907468359     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2014/123079     Document Type: Article

References (21)

1. V. Válková, J. Polák, M. Marková et al., "Minimal residual disease detectable by quantitative assessment of WT1 gene before allogeneic stem cell transplantation in patients in first remission of acute myeloid leukemia has an impact on their future prognosis," Clinical Transplantation, vol. 27, pp. E21-E29, 2013.
2. J. Polák, H. Hájková, J. Maalaufová-Soukupová et al., "Estimation of molecular upper remission limit for monitoring minimal residual disease in peripheral blood of acute myeloid leukemia patients by WT1 expression," Experimental and Therapeutic Medicine, vol. 3, pp. 129-133, 2012.
3. H. Miwa, M. Beran, and G. F. Saunders, "Expression of the Wilms' tumor gene (WT1) in human leukemias," Leukemia, vol. 6, no. 5, pp. 405-409, 1992.
4. K. Inoue, H. Ogawa, Y. Sonoda et al., "Aberrant overexpression of the Wilms tumor gene (WT1) in human leukemia," Blood, vol. 89, no. 4, pp. 1405-1412, 1997.
5. M. Weisser, W. Kern, S. Rauhut et al., "Prognostic impact of RT-PCR-based quantification WT1 gene expression during MRD monitoring of acute myeloid leukemia," Leukemia, vol. 19, no. 8, pp. 1416-1423, 2005.
6. D. Cilloni, A. Renneville, F. Hermitte et al., "Real-time quantitative polymerase chain reaction detection of minimal residual disease by standardized WT1 assay to enhance risk stratification in acute myeloid leukemia: a European LeukemiaNet Study," Journal of Clinical Oncology, vol. 27, no. 31, pp. 5195-5201, 2009.
7. J. F. Nomdedéu, M. Hoyos, M. Carricondo et al., "Bone marrow WT1 levels at diagnosis, post-induction and post-intensification in adult de novo AML," Leukemia, vol. 27, pp. 2157-2164, 2013.
8. G. Rossi, M. M. Minervini, L. Melillo et al., "Predictive role of minimal residual disease and log clearance in acute myeloid leukemia: a comparison between multiparameter flow cytometry and Wilm's tumor 1 levels," Annals of Hematology, vol. 93, no. 7, pp. 1149-1157, 2014.
9. P. Paschka, G. Marcucci, A. S. Ruppert et al., "Wilms' tumor 1 gene mutations independently predict poor outcome in adults with cytogenetically normal acute myeloid leukemia: a cancer and leukemia group B study," Journal of Clinical Oncology, vol. 26, no. 28, pp. 4595-4602, 2008.
10. J. X. Gray, L. McMillen, P. Mollee et al., "WT1 expression as a marker of minimal residual disease predicts outcome in acute myeloid leukemia when measured post-consolidation," Leukemia Research, vol. 36, no. 4, pp. 453-458, 2012.
11. S. Pozzi, S. Geroldi, E. Tedone et al., "Leukaemia relapse after allogeneic transplants for acute myeloid leukaemia: predictive role of WT1 expression," British Journal of Haematology, vol. 160, no. 4, pp. 503-509, 2013.
12. M. Kwon, C. Martínez-Laperche, M. Infante et al., "Evaluation of minimal residual disease by real-time quantitative PCR of Wilms' tumor 1 expression in patients with acute myelogenous leukemia after allogeneic stem cell transplantation: correlation with flow cytometry and chimerism," Biology of Blood and Marrow Transplantation, vol. 18, no. 8, pp. 1235-1242, 2012.
13. E. Barragán, J. Cervera, P. Bolufer et al., "Prognostic implications of Wilms' tumor gene (WT1) expression in patients with de novo acute myeloid leukemia," Haematologica, vol. 89, no. 8, pp. 926-933, 2004.
14. A. Candoni, M. Tiribelli, E. Toffoletti et al., "Quantitative assessment of WT1 gene expression after allogeneic stem cell transplantation is a useful tool for monitoring minimal residual disease in acute myeloid leukemia," European Journal of Haematology, vol. 82, no. 1, pp. 61-68, 2009.
15. A. Candoni, E. Toffoletti, R. Gallina et al., "Monitoring of minimal residual disease by quantitative WT1 gene expression following reduced intensity conditioning allogeneic stem cell transplantation in acute myeloid leukemia," Clinical Transplantation, vol. 25, no. 2, pp. 308-316, 2011.
16. H. Ogawa, H. Tamaki, K. Ikegame et al., "The usefulness of monitoring WT1 gene transcripts for the prediction and management of relapse following allogeneic stem cell transplantation in acute type leukemia," Blood, vol. 101, no. 5, pp. 1698-1704, 2003.
17. X. S. Zhao, C. H. Yan, D. H. Liu et al., "Combined use of WT1 and flow cytometry monitoring can promote sensitivity of predicting relapse after allogeneic HSCT without affecting specificity," Annals of Hematology, vol. 92, no. 8, pp. 1111-1119, 2013.
18. J. Yoon, H. Kim, S. Shin et al., "Serial measurement of WT1 expression and decrement ratio until hematopoietic cell transplantation as a marker of residual disease in patients with cytogenetically normal acute myelogenous leukemia," Biology of Blood and Marrow Transplantation, vol. 19, no. 6, pp. 958-966, 2013.
19. X.-S. Zhao, S. Jin, H.-H. Zhu et al., "Wilms tumor gene 1 expression: an independent acute leukemia prognostic indicator following allogeneic hematopoietic SCT," Bone Marrow Transplantation, vol. 47, no. 4, pp. 499-507, 2012.
20. H. Döhner, E. H. Estey, S. Amadori et al., "Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet," Blood, vol. 115, no. 3, pp. 453-474, 2010.
21. E. R. Kaplan and P. Mejer, "Non parametric estimation from incomplete observation," Journal of the American Statistical Association, vol. 53, pp. 457-481, 1958.